$REPL

Replimune Group (REPL): Ridgeback Capital now reports 3.5% ownership stake

Replimune Group, Inc. said Ridgeback Capital entities filed an amended Schedule 13G/A. Ridgeback previously reported 7,310,656 shares (8.7%) as of June 25, 2026. As of Aug. 13, 2026, each reporting person reports 2,912,373 shares (3.5%) with shared voting and dispositive power, indicating ownership of 5% or less.

Original reporting
Published Aug 14, 2026, 8:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 15, 2026, 7:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$REPL
Neutral
medium confidence
Mentioned
$REPL
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$REPLNeutralLow
01

Why it matters

Beneficial ownership fell to 3.5% (from 8.7%), with shared voting and dispositive power, and the filing indicates ownership of 5% or less of the class.

02

Market read

This is a shareholder disclosure that can affect perceptions of influence, but it does not provide new fundamentals or a direct catalyst for operations.

03

What to watch

Traders should monitor whether Ridgeback files additional 13D/13G amendments, changes in intent, or whether other holders step up, since control dynamics can change without large headline moves.

Relevance 4/10Novelty 4/10Timing: latest ownership update filed Aug. 14, 2026 for Aug. 13, 2026 position

Background

The article summarizes an amended Schedule 13G/A from Ridgeback Capital entities reporting beneficial ownership changes in Replimune Group’s common stock.

Company-level read

Ticker impact

$REPLNeutralMedium confidence
Context

Replimune received an amended Schedule 13G showing Ridgeback Capital cut its beneficial ownership to 3.5% from 8.7% as of Aug. 13, 2026.

Expected impact

Likely limited near-term impact; watch for follow-on filings or whether the holder exits further.

Evidence & confidence

The filing is a regulatory ownership update (Schedule 13G/A) with no stated intent to gain control, and it reports ownership of 5% or less, suggesting reduced influence versus the prior 8.7%.

Market effects

Minimal, as this is company-specific shareholder disclosure rather than a sector catalyst.

None indicated; US SEC filing for a US-listed issuer.

None indicated.

Counterpoint

The reduction may reflect administrative rebalancing or partial sales without any negative thesis on the business.

Key entities

  • Replimune Group, Inc.

    Subject of the Schedule 13G/A ownership update summarized in the article.

  • Ridgeback Capital Investments L.P.

    Reporting person entity that reduced beneficial ownership to 2,912,373 shares, 3.5% as of Aug. 13, 2026.

  • Ridgeback Capital Investments LLC

    Reporting person entity with shared voting and dispositive power over the same pool of shares.

  • Ridgeback Capital Management LLC

    Entity described as controlling investment management decisions for the holdings.

Related articles

$REPLLowAI 8/10

Replimune Group Lawsuit: Company Asks Court to Dismiss Securities Case Over RP1 FDA Approval Process - TipRanks.com

Replimune Group (NASDAQ: REPL) and its leaders filed a motion to dismiss a lawsuit alleging securities violations over statements about its melanoma treatment RP1's FDA approval process. The investors claim Replimune misled them about FDA feedback on the IGNYTE trial. Replimune argues it disclosed risks and that the FDA ultimately approved RP1 in August 2026.

$REPLMed

Replimune Group, Inc. (REPL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz invites Replimune Group (REPL) investors who suffered losses to join a securities fraud class action lawsuit. The complaint alleges misstatements and omissions about the company's business and prospects between October 20, 2025, and April 10, 2026, including FDA concerns and data submission issues. Investors have until October 5, 2026, to participate.

$REPLMed

REPL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ:REPL) and certain officers, alleging securities law violations. The lawsuit covers investors who acquired Replimune securities between October 20, 2025, and April 10, 2026. The complaint claims Replimune made false statements and omitted key information regarding FDA concerns and clinical trial data. Investors have until October 5, 2026, to request lead plaintiff status.